Noom launches GLP-1 Rx program with compounded semaglutide at competitive prices.

Noom has launched a GLP-1 Rx program offering compounded semaglutide, an off-brand alternative to Novo Nordisk's Ozempic and Wegovy, at competitive prices—$149 for the first month and $279 afterward. The program emphasizes behavior modification for sustainable weight loss and includes a taper-off option. However, compounded versions may pose safety risks due to manual dosing, leading to potential overdoses. The market for affordable weight loss medications is becoming increasingly competitive.